Ocular Therapeutix Company Profile (NASDAQ:OCUL)

About Ocular Therapeutix

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company's product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company's lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCUL
  • CUSIP:
Key Metrics:
  • Previous Close: $8.22
  • 50 Day Moving Average: $7.83
  • 200 Day Moving Average: $7.51
  • 52-Week Range: $4.04 - $14.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.62
  • P/E Growth: 0.00
  • Market Cap: $204.51M
  • Outstanding Shares: 24,879,000
  • Beta: 1.54
Profitability:
  • Net Margins: -2,346.47%
  • Return on Equity: -56.23%
  • Return on Assets: -44.41%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 9.32%
  • Quick Ratio: 9.31%
Additional Links:
Companies Related to Ocular Therapeutix:

Analyst Ratings

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.31 (171.37% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2017Cantor FitzgeraldInitiated CoverageOverweight$35.00View Rating Details
1/24/2017BTIG ResearchReiterated RatingBuy$13.00View Rating Details
11/15/2016RBC Capital MarketsReiterated RatingOutperform$30.00 -> $32.00View Rating Details
11/15/2016Royal Bank Of CanadaBoost Price TargetOutperform$30.00 -> $32.00View Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84View Rating Details
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/7/2016Morgan StanleyReiterated RatingOverweight$17.00 -> $16.00View Rating Details
8/5/2015NomuraInitiated CoverageBuy$46.00View Rating Details
3/11/2015Oppenheimer Holdings, Inc.Boost Price TargetOutperform$42.00 -> $49.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/9/2016Q316($0.50)($0.39)$0.47 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)ViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)ViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)ViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.50 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
Current Year EPS Consensus Estimate: $-1.74 EPS
Next Year EPS Consensus Estimate: $-2.27 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocular Therapeutix (NASDAQ:OCUL)
Insider Ownership Percentage: 30.60%
Institutional Ownership Percentage: 66.59%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
DateHeadline
News IconBiotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS) (NASDAQ:OCUL)
feedproxy.google.com - February 23 at 2:12 PM
News IconReviewing the Levels for Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Midway Monitor (NASDAQ:OCUL)
midwaymonitor.com - February 23 at 9:19 AM
News IconStock Update: Estimates & Target in Focus for Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Aiken Advocate (NASDAQ:OCUL)
aikenadvocate.com - February 23 at 12:08 AM
marketexclusive.com logoOCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) Files An 8-K Other ... - Market Exclusive (NASDAQ:OCUL)
marketexclusive.com - February 23 at 12:08 AM
News IconMarket Update: Watching Increased Volatility on Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Aiken Advocate (NASDAQ:OCUL)
aikenadvocate.com - February 22 at 7:06 PM
finance.yahoo.com logoOcular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular ... - Yahoo Finance (NASDAQ:OCUL)
finance.yahoo.com - February 22 at 7:06 PM
News IconMost Active Volume Stock: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - HugoPress (NASDAQ:OCUL)
hugopress.com - February 22 at 9:04 AM
News IconAnalyst Target Update on Ocular Therapeutix, Inc. (NASDAQ:OCUL ... - Rockville Register (NASDAQ:OCUL)
rockvilleregister.com - February 21 at 5:53 PM
News IconHot Stocks Among Investors: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Comstock Resources, Inc. (NYSE:CRK) - Post Analyst (NASDAQ:OCUL)
postanalyst.com - February 21 at 5:53 PM
News IconStock Price of Ocular Therapeutix, Inc. (OCUL) Increases 19.76 ... - Highland Mirror (NASDAQ:OCUL)
www.highlandmirror.com - February 21 at 5:53 PM
News IconEquity in Focus: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - BVN (NASDAQ:OCUL)
bvnewsjournal.com - February 18 at 11:49 AM
News IconOcular Therapeutix, Inc. (NASDAQ:OCUL) Charts Indicating Positive Momentum - Winfield Review (NASDAQ:OCUL)
winfieldreview.com - February 15 at 3:28 AM
News IconSaudi Arabia to allow women to use gyms 'to lose weight' (NASDAQ:OCUL)
ekosvoice.com - February 14 at 10:20 PM
News IconStocks in the Spotlight Chesapeake Energy Corporation (NYSE:CHK), Ocular Therapeutix Inc (NASDAQ:OCUL) - Financial Breaking News (NASDAQ:OCUL)
wsbreakingnews.com - February 13 at 9:36 AM
News Icon7 most outstanding Indian Americans (NASDAQ:OCUL)
www.americanbazaaronline.com - February 11 at 7:06 PM
News IconWhy Ocular Therapeutix Inc Jumped Higher Today - Fox Business (NASDAQ:OCUL)
www.foxbusiness.com - February 11 at 12:59 AM
streetinsider.com logoForm SC 13G/A OCULAR THERAPEUTIX, INC Filed by: FMR LLC - StreetInsider.com (NASDAQ:OCUL)
www.streetinsider.com - February 10 at 7:56 PM
smarteranalyst.com logoTwo Biotech Stocks Analysts Are Talking About: Immunomedics, Inc. (IMMU), Ocular Therapeutix Inc (OCUL) - Smarter Analyst (NASDAQ:OCUL)
www.smarteranalyst.com - February 10 at 7:56 PM
fool.com logoWhy Ocular Therapeutix Inc Jumped Higher Today - Motley Fool (NASDAQ:OCUL)
www.fool.com - February 10 at 7:56 PM
fool.com logoWhy Ocular Therapeutix Inc Jumped Higher Today (NASDAQ:OCUL)
www.fool.com - February 10 at 7:56 PM
News IconTale of the Tape: Technical Recap for Ocular Therapeutix Inc (OCUL) - Rives Journal (NASDAQ:OCUL)
rivesjournal.com - February 10 at 1:06 AM
finance.yahoo.com logoOcular TherapeutixTM to Present at Three Upcoming Investor Conferences (NASDAQ:OCUL)
finance.yahoo.com - February 9 at 8:05 PM
istreetwire.com logoStock's Trend Analysis Report: Headwaters Incorporated (HW), Ocular Therapeutix, Inc. (OCUL), EnteroMedics Inc ... - iStreetWire (NASDAQ:OCUL)
istreetwire.com - January 31 at 8:01 AM
News IconHigh Volatility Moving the Needle For Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Wall Street Beacon (NASDAQ:OCUL)
wsbeacon.com - January 31 at 8:01 AM
marketexclusive.com logoOCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:OCUL)
marketexclusive.com - January 29 at 12:08 AM
News IconStocks in Concern on New Development: Sanofi (NYSE:SNY), Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Street Wise Report (press release) (blog) (NASDAQ:OCUL)
streetwisereport.com - January 29 at 12:08 AM
News IconFollowing FCF Scores for Ocular Therapeutix, Inc. (NASDAQ:OCUL) - The Tribune (NASDAQ:OCUL)
lakecitytribune.com - January 28 at 5:27 AM
News IconStocks in Concern on New Development: Sanofi (NYSE:SNY ... - Street Wise Report (press release) (blog) (NASDAQ:OCUL)
streetwisereport.com - January 27 at 5:03 AM
marketexclusive.com logoOCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) Files An 8-K Other Events - Market Exclusive (NASDAQ:OCUL)
marketexclusive.com - January 27 at 5:03 AM
News IconOcular Therapeutix, Inc. (NASDAQ:OCUL) has 1 Year Target Estimate of $28.4 - The Newburgh Press (NASDAQ:OCUL)
newburghpress.com - January 27 at 5:03 AM
News IconStock Seesawing as Volatility Sweeps in on Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Wall Street Beacon (NASDAQ:OCUL)
wsbeacon.com - January 27 at 5:03 AM
biz.yahoo.com logoOCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State (NASDAQ:OCUL)
biz.yahoo.com - January 27 at 12:00 AM
News IconThe Ocular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Buy" by Brokerages (NASDAQ:OCUL)
prensariotiretail.com - January 26 at 3:48 AM
News IconShares Springing Higher Ahead of the Bell: Ocular Therapeutix, Inc. (NASDAQ:OCUL) (NASDAQ:OCUL)
thecelebritytruth.com - January 25 at 10:48 PM
capitalcube.com logoETFs with exposure to Ocular Therapeutix, Inc. : January 25, 2017 (NASDAQ:OCUL)
us.rd.yahoo.com - January 25 at 10:48 PM
News IconIs Trouble Brewing For This Stock? Shares Gapping Lower: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Aiken Advocate (NASDAQ:OCUL)
aikenadvocate.com - January 25 at 5:46 AM
News IconErratic Volume Stretches This Stock Mid-Session: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Wall Street Beacon (NASDAQ:OCUL)
wsbeacon.com - January 25 at 12:46 AM
News IconChart Level Analysis on Shares of Ocular Therapeutix Inc (OCUL) - Sherwood Daily (NASDAQ:OCUL)
sherwooddaily.com - January 24 at 7:45 PM
News IconOcular Therapeutix Inc (NASDAQ:OCUL) Volatility is Low on a Downward Trend - Live Trading News (NASDAQ:OCUL)
www.livetradingnews.com - January 24 at 7:45 PM
reuters.com logoBRIEF-Ocular Therapeutix Inc announces pricing of public offering of common stock - Reuters (NASDAQ:OCUL)
www.reuters.com - January 24 at 7:45 PM
finance.yahoo.com logo8:02 am Ocular Therapeutix prices registered underwritten public offering of 3,571,429 shares of its common stock at $7.00/share (NASDAQ:OCUL)
finance.yahoo.com - January 24 at 7:45 PM
finance.yahoo.com logoOcular Therapeutics Sinks Following Secondary Offering (NASDAQ:OCUL)
finance.yahoo.com - January 24 at 7:45 PM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Wall Street Beacon (NASDAQ:OCUL)
wsbeacon.com - January 24 at 9:01 AM
finance.yahoo.com logoOcular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock (NASDAQ:OCUL)
finance.yahoo.com - January 24 at 9:00 AM
News IconVC Score In Focus for Ocular Therapeutix, Inc. (NASDAQ:OCUL) - The Tribune (NASDAQ:OCUL)
lakecitytribune.com - January 24 at 12:21 AM
News IconNottingham Advisors Cuts Position in Ocular Therapeutix Inc (OCUL) - Highland Mirror (NASDAQ:OCUL)
www.highlandmirror.com - January 24 at 12:21 AM
News IconOcular Therapeutix Inc (NASDAQ:OCUL) Heffx Trading Outlook - Live Trading News (NASDAQ:OCUL)
www.livetradingnews.com - January 24 at 12:21 AM
News IconPriming The Pump: Stock Volatility Spotted in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Wall Street Beacon (NASDAQ:OCUL)
wsbeacon.com - January 24 at 12:21 AM
smarteranalyst.com logoBTIG Weighs In on Ocular Therapeutix Inc (OCUL) Following NDA Resubmission (NASDAQ:OCUL)
www.smarteranalyst.com - January 23 at 7:20 PM
finance.yahoo.com logoOcular Therapeutix, Inc. Announces Public Offering of Common Stock (NASDAQ:OCUL)
finance.yahoo.com - January 23 at 7:20 PM

Social

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?

7 analysts have issued 1 year target prices for Ocular Therapeutix's shares. Their forecasts range from $5.84 to $35.00. On average, they anticipate Ocular Therapeutix's share price to reach $22.31 in the next year.

When will Ocular Therapeutix announce their earnings?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

  • Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)
  • According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (10/12/2016)

Who owns Ocular Therapeutix stock?

Ocular Therapeutix's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (10.53%), SV Life Sciences Advisers LLC (6.45%), State Street Corp (0.96%), Renaissance Technologies LLC (0.58%), Opaleye Management Inc. (0.38%) and A.R.T. Advisors LLC (0.21%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Charles M Warden, James Fortune and Svlsf Iv, Llc.

Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and SV Life Sciences Advisers LLC.

Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?

Ocular Therapeutix's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Opaleye Management Inc., A.R.T. Advisors LLC, State Street Corp, Dynamic Technology Lab Private Ltd, Pacad Investment Ltd., Trexquant Investment LP and Ellington Management Group LLC.

How do I buy Ocular Therapeutix stock?

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ocular Therapeutix stock cost?

One share of Ocular Therapeutix stock can currently be purchased for approximately $8.22.

Ocular Therapeutix (NASDAQ:OCUL) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Earnings History Chart

Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Dividend History Chart

Dividend Payments by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Last Updated on 2/23/2017 by MarketBeat.com Staff